Microbiology of Acute Cholangitis and Cholecystitis and Antimicrobial Susceptibility
Main Article Content
Abstract
Background: Acute cholecystitis and cholangitis are life-threatening if not treated promptly. Empiric antibiotic therapy is crucial, relying on local studies of bile culture for guidance.
Objective: To identify the microbiological and antibiotic susceptibilities of organisms in bile cultures of patients with acute cholangitis and cholecystitis.
Materials and Methods: Adults diagnosed with acute cholangitis and/or cholecystitis at the Hospital Regional ISSSTE Puebla (2022-2023) underwent bile aspiration via laparoscopy or open surgery. Microorganisms were isolated from bile cultures and antibiograms were obtained. Patients were classified according to severity according to the Tokyo Guidelines 2018.
Results: A total of 88 patients with bile cultures for cholangitis/cholecystitis were included. Fourteen percent of cultures showed no bacterial growth, and E. coli was the most common pathogen with significant antibiotic resistance. Multivariate analysis identified recent antimicrobial therapy (p <0.03), concomitant malignancy (p <0.001), and age >65 years (p <0.0001) as factors associated with resistant bacteria. Thirty-day mortality was 2.3%.
Conclusions: Empirical antimicrobial therapy based on TG 2018 was effective across all severity grades.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Gomi H, Solomkin JS, Schlossberg D, et al.: Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepato-Biliary-Pancreat Sci. 2018, 25:3–16. 10.1002/jhbp.518
II. Lavillegrand J-R, Mercier-Des-Rochettes E, Baron E, et al.: Acute cholangitis in intensive care units: clinical, biological, microbiological spectrum and risk factors for mortality: a multicenter study. Crit Care. 2021, 25:49. 10.1186/s13054-021-03480-1
III. Shenoy SM, Shenoy S, Gopal S, Tantry BV, Baliga S, Jain A: Clinicomicrobiological analysis of patients with cholangitis. Indian J Med Microbiol. 2014, 32:157–60. 10.4103/0255-0857.129802
IV. Karasawa Y, Kato J, Kawamura S, et al.: Risk Factors for Acute Cholangitis Caused by Enterococcus faecalis and Enterococcus faecium. Gut Liver. 2021, 15:616–24. 10.5009/gnl20214
V. Butte JM, Hameed M, Ball CG: Hepato-pancreato-biliary emergencies for the acute care surgeon: etiology, diagnosis and treatment. World J Emerg Surg WJES. 2015, 10:13. 10.1186/s13017-015-0004-y
VI. Coccolini F, Sartelli M, Catena F, et al.: Antibiotic resistance pattern and clinical outcomes in acute cholecystitis: 567 consecutive worldwide patients in a prospective cohort study. Int J Surg Lond Engl. 2015, 21:32–7. 10.1016/j.ijsu.2015.07.013
VII. Chawki S, Sokal A, Duprilot M, et al.: Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes. Eur J Clin Microbiol Infect Dis. 2021, 40:1773–7. 10.1007/s10096-021-04158-w
VIII. Gazdik MA, Coombs J, Burke JP, Lopansri BK: Comparison of Two Culture Methods for Use in Assessing Microbial Contamination of Duodenoscopes. J Clin Microbiol. 2016, 54:312–6. 10.1128/JCM.02754-15
IX. Yokoe M, Hata J, Takada T, et al.: Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepato-Biliary-Pancreat Sci. 2018, 25:41–54. 10.1002/jhbp.515
X. Gomi H, Takada T, Hwang T-L, et al.: Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepato-Biliary-Pancreat Sci. 2017, 24:310–8. 10.1002/jhbp.452
XI. Sawyer RG, Claridge JA, Nathens AB, et al.: Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015, 372:1996–2005. 10.1056/NEJMoa1411162
XII. Goo JC, Seong MH, Shim YK, et al.: Extended Spectrum-β-Lactamase or Carbapenemase Producing Bacteria Isolated from Patients with Acute Cholangitis. Clin Endosc. 2012, 45:155–60. 10.5946/ce.2012.45.2.155
XIII. Mazuski JE, Tessier JM, May AK, et al.: The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect. 2017, 18:1–76. 10.1089/sur.2016.261
XIV. Reuken PA, Torres D, Baier M, et al.: Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis. PloS One. 2017, 12:e0169900.
1371/journal.pone.0169900
XV. Kwon JS, Han J, Kim TW, et al.: Changes in causative pathogens of acute cholangitis and their antimicrobial susceptibility over a period of 6 years. Korean J Gastroenterol Taehan Sohwagi Hakhoe Chi. 2014, 63:299–307. 10.4166/kjg.2014.63.5.299
XVI. Masuda S, Koizumi K, Uojima H, et al.: Effect of Antibiotic Resistance of Pathogens on Initial Antibiotic Therapy for Patients With Cholangitis. Cureus. 13:e18449. 10.7759/cureus.18449
XVII. Negm AA, Schott A, Vonberg R-P, et al.: Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc. 2010, 72:284–91. 10.1016/j.gie.2010.02.043
XVIII. Tian S, Li K, Tang H, et al.: Clinical characteristics of Gram-negative and Gram-positive bacterial infection in acute cholangitis: a retrospective observational study. BMC Infect Dis. 2022, 22:1–10.
XIX. Kwakman JA, Rauwers AW, Klaassen CHW, Bruno MJ, Vos MC: Investigation of possible transmission of a susceptible microorganism through a contaminated duodenoscope; a case report. Antimicrob Resist Infect Control. 2021, 10:127. 10.1186/s13756-021-00996-7
XX. Zhao J, Wang Q, Zhang J: Changes in Microbial Profiles and Antibiotic Resistance Patterns in Patients with Biliary Tract Infection over a Six-Year Period. Surg Infect. 2019, 20:480–5. 10.1089/sur.2019.041
XXI. Zhao C, Liu S, Bai X, Song J, Fan Q, Chen J: A Retrospective Study on Bile Culture and Antibiotic Susceptibility Patterns of Patients with Biliary Tract Infections. Evid Based Complement Alternat Med. 2022, 2022:1–11. 10.1155/2022/9255444